Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug DiscoveryCollaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics
